AAD consensus statement on psoriasis therapies

Callen, Jeffrey P.; Krueger, Gerald G.; Lebwohl, Mark; McBurney, Elizabeth I.; Mease, Philip J.; Menter, Alan; Paller, Amy S.; Pariser, David M.; Weinblatt, Michael E.; Zimmerman, Gail

doi:10.1016/s0190-9622(03)01870-x

Cited by 104 publications

(81 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although there is substantial variation, the trend among the responders was to prefer phototherapy followed by acitretin (±UV) and then MTX or CsA, which shows some evidence of awareness of recent guidelines and expert opinions [1,2,3,4,5, 25, 26]. However, PUVA was significantly more likely to be preferred compared to UVB in healthy psoriasis adults, which is in disagreement with most recommendations but confirms the lack of consensus about UV therapy between dermatologists in the USA and Europe [27, 28].…”

Section: Discussionmentioning

confidence: 99%

Dermatologists’ Views and Opinions about Photo(chemo)therapy and Conventional Systemic Psoriasis Therapies: Results from a Belgian Survey

Nijsten

Lambert

2006

Dermatology

View full text Add to dashboard Cite

Background: Experts’ opinions about old and new psoriasis therapies are well documented. Objectives: To document the views and opinions of a large, diverse group of dermatologists about psoriasis treatment. Participants/Methods: A survey was conducted among Belgian dermatologists. In addition to demographic and professional characteristics, the questionnaire assessed the self-rated level of experience, frequency of use, preference and considerations regarding UVB, PUVA, methotrexate (MTX), cyclosporin (CsA) and acitretin. Multivariate logistic regression analyses were performed to investigate predictors of these dermatologist-based outcomes. Results: Of the 628 contacted dermatologists, 310 responded (response rate of 49.3%). The dermatologists were significantly more experienced with photo(chemo)therapy than with systemic agents (p ≤ 0.02); about half reported none or little experience with MTX and CsA. Also, photo(chemo)therapies were significantly more frequently used than systemic drugs (p ≤ 0.01). In the last year, almost 40% had not used and less than 10% had used MTX or CsA more than 10 times. Despite the limitations of PUVA, it was preferred to UVB, followed by acitretin (± phototherapy), and MTX and CsA were considered final options by most dermatologists. After adjusting for confounding variables, age, years in practice, seeing and treating more patients, residency programme and/or access to UV therapy were significantly associated with limited experience, regular use and/or preference of studied therapies. Conclusion: Either a substantial proportion of the dermatologists does not need or wish to use conventional systemic psoriasis therapies or they may need better and more uniform training during and after their residency. This may improve patient care and patient selection for other treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

Dermatologists’ Views and Opinions about Photo(chemo)therapy and Conventional Systemic Psoriasis Therapies: Results from a Belgian Survey

Nijsten

Lambert

2006

Dermatology

View full text Add to dashboard Cite

show abstract

“…Patients with psoriasis, for instance, often show symptoms of depression [9] and have an impaired sexual life [10], both of which influence HRQoL. Nowadays, it is widely understood and acknowledged in the medical community that HRQoL assessments provide a comprehensive outcome measure leading to better treatment strategies than objective clinical measurements alone [11]. …”

Section: Introductionmentioning

confidence: 99%

Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in Germany

Augustin¹,

Krüger

Radtke³

et al. 2008

Dermatology

237

230

View full text Add to dashboard Cite

Background: Plaque-type psoriasis produces significant morbidity, has negative effects on patients’ health-related quality of life (HRQoL), and represents an economic burden. Objectives: The assessment of disease severity, HRQoL and health care in plaque-type psoriasis in everyday German medical practice. Methods: Details of patients with plaque-type psoriasis were recorded by 48 dermatologists in Germany. During the visit, demographic data, medical history, previous and current treatments, occupational impairment, the current state of the disease (measured by the Psoriasis Area and Severity Index; PASI), overall lesion severity, and HRQoL were evaluated. Results: In total, 1,511 plaque-type psoriasis patients were included. The average PASI score was 12.0. The average Dermatology Life Quality Index score was 8.6. Among the patients with the severest psoriasis (PASI >20), only 45.4% had ever been prescribed systemic treatments. Conclusions: Psoriasis patients have a reduced HRQoL and are not sufficiently treated in practice. A more widespread use of systemic treatment and the definition of treatment goals are essential to improve the standard of care for psoriasis patients.

show abstract

“…3) Its efficacy has been demonstrated in many clinical trials. [4][5][6][7] In a clinical setting, the typical practice of cyclosporine dosage adjustments is frequently used to determine its concentration and then adjust the dosage by a trial-and-error approach. However, controversy still surrounds the dosage regimen, therapeutic concentration range, and method of therapeutic drug monitoring of cyclosporine in the treatment of collagen diseases [8][9][10] ; the pharmacokinetics of cyclosporine show large variations in blood levels following its oral or intravenous administration, not only interindividually, but also intraindividually, 11) especially after oral dosing.…”

mentioning

confidence: 99%

Population Pharmacokinetic Approach to the Use of Low Dose Cyclosporine in Patients with Connective Tissue Diseases

Tsuji

Iwanaga

Mizoguchi

et al. 2015

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

AAD consensus statement on psoriasis therapies

Cited by 104 publications

References 4 publications

Dermatologists’ Views and Opinions about Photo(chemo)therapy and Conventional Systemic Psoriasis Therapies: Results from a Belgian Survey

Dermatologists’ Views and Opinions about Photo(chemo)therapy and Conventional Systemic Psoriasis Therapies: Results from a Belgian Survey

Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in Germany

Population Pharmacokinetic Approach to the Use of Low Dose Cyclosporine in Patients with Connective Tissue Diseases

Contact Info

Product

Resources

About